Patents by Inventor Margaret Moreland
Margaret Moreland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5648344Abstract: Ligands that bind to human selectin receptors are disclosed. The ligands are formulated with excipient carriers to form compositions which are administered to treated condition such as inflammation. The ligands have the structural formula III ##STR1## or molecules which have hydrogen bond donor groups equivalent to the circled groups with respect to their ability to form hydrogen bonds with a selectin under physiological conditions.Type: GrantFiled: July 30, 1992Date of Patent: July 15, 1997Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber, Narasinga Rao
-
Patent number: 5470842Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation.Type: GrantFiled: March 2, 1992Date of Patent: November 28, 1995Assignee: Glycomed, IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5428025Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of F and G is hydrogen and one is an N-acetyl neuraminic acid residue on the terminal unit and are both hydrogen on any other unit; J is hydrogen, a lactosylceramide or a linking group and K is hydrogen or a fucose residue and n is an integer of from 1 to 10 (preferably 3 or 4) with the proviso that n and K are defined such that at least one K is a fucose residue.Type: GrantFiled: March 2, 1992Date of Patent: June 27, 1995Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5276140Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--XwhereinL is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from: ##STR1## wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue briding the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected from--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --a)wherein each n2 is independently 2-4 and ##STR2## wherein n3 is 2-6. Also claimed are hydrazides, semicarbazides, and thiosemicarbazides of .omega.-mercaptocarboxylic acids which lack SPACER diamine.Type: GrantFiled: January 9, 1991Date of Patent: January 4, 1994Assignee: Cetus Oncology CorporationInventors: Danute E. Nitecki, Margaret Moreland
-
Patent number: 5252603Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## wherein n=1-6R=CH.sub.3, CF.sub.3, --CO.sub.2 R.sup.IV, ##STR2## R.sup.I, R.sup.II =H, F, CH.sub.3, or ##STR3## R.sup.III =H, ##STR4## or tetrazolyl R.sup.IV =H, or alkyland that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: October 12, 1993Assignee: Cetus CorporationInventors: Danute E. Nitecki, Lois Aldwin, Corey H. Levenson, Margaret Moreland, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5241078Abstract: This invention discloses heterobifunctional coupling agents for making a wide array of molecular conjugates. The agents contain a sterically hindered thiol, linked through a spacer arm to a second group reactive toward nucleophiles such as 1.degree. and 2.degree. amines or reactive thiols that are present on biological and organic materials. The coupling agents are useful for making conjugates containing a sterically hindered linkage.Type: GrantFiled: February 14, 1992Date of Patent: August 31, 1993Assignee: Cetus OncologyInventors: Margaret Moreland, I. Lawrence Greenfield, Danute E. Nitecki
-
Patent number: 5216005Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: June 1, 1993Assignee: Cetus CorporationInventors: Danute E. Nitecki, Lois Aldwin, Corey H. Levenson, Margaret Moreland, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5211937Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation.Type: GrantFiled: April 11, 1991Date of Patent: May 18, 1993Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5211936Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of F and G is hydrogen and one is an N-acetyl neuraminic acid residue on the terminal unit and are both hydrogen on any other unit; J is hydrogen, a lactosylceramide or a linking group and K is hydrogen or a fucose residue and n is an integer of from 1 to 10 (preferably 3 or 4) with the proviso that n and K are defined such that at least one K is a fucose residue.Type: GrantFiled: July 30, 1990Date of Patent: May 18, 1993Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5173482Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: December 22, 1992Assignee: Cetus CorporationInventors: Danute E. Nitecki, Margaret Moreland, Lois Aldwin, Corey H. Levenson, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5153265Abstract: A biologically active CSF-1 protein is selectively conjugated via certain amino acid residues or carbohydrate moieties to a water-soluble polymer selected from polyethylene glycol or polypropylene glycol homopolymers, polyoxyethylated polyols, or polyvinyl alcohol. The resulting conjugated CSF-1 is biologically active and has increased circulating half-life in mammals, compared to that of the unconjugated protein. The conjugated CSF-1 may be used to stimulate the immune response or to provide more cells to be stimulated.Type: GrantFiled: August 30, 1990Date of Patent: October 6, 1992Assignee: Cetus CorporationInventors: Paula J. Shadle, Kirston E. Koths, Margaret Moreland, Nandini Katre, Walter J. Laird, Lois Aldwin, Danute E. Nitecki, John D. Young
-
Patent number: 5143712Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of A and B is hydrogen and one is an N-acetyl neuraminic acid residue; D and E are each independently hydrogen or a fucose residue; n is an integer of from 0 to 10 with the proviso that if n is 0, E is a fucose residue; F is hydrogen, a lactosylceramide residue or a linking group; and molecules equivalent to a compound of formula I regarding its ability to bind to an ELAM-1 receptor to the same degree as a compound of formula I.Type: GrantFiled: January 7, 1991Date of Patent: September 1, 1992Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5034514Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--XwhereinL is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from: --CO--Y--CONHNH.sub.2, a hydrazide; ##STR1## a hydrazine; ##STR2## a hydrazine; --CO--Y--NH--CONHNH.sub.2, a semicarbazide; and --CO--Z--NH--CSNHNH.sub.2, a thiosemicarbazide;wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue briding the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected froma) --(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 -- wherein each n2 is independently 2-4 andb) ##STR3## wherein n3 is 2-6.Type: GrantFiled: October 12, 1988Date of Patent: July 23, 1991Assignee: Cetus CorporationInventors: Danute E. Nitecki, Margaret Moreland
-
Patent number: 4895872Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: March 15, 1989Date of Patent: January 23, 1990Assignee: Cetus CorporationInventors: Danute E. Nitecki, Margaret Moreland, Lois Aldwin, Corey H. Levenson, Irwin Braude, David F. Mark, Henry Rapaport
-
Patent number: 4847325Abstract: A biologically active CSF-1 protein is selectively conjugated via certain amino acid residues or carbohydrate moieties to a water-soluble polymer selected from polyethylene glycol or polypropylene glycol homopolymers, polyoxyethylated polyols, or polyvinyl alcohol. The resulting conjugated CSF-1 is biologically active and has increased circulating half-life in mammals, compared to that of the unconjugated protein. The conjugated CSF-1 may be used to stimulate the immune response or to provide more cells to be stimulated.Type: GrantFiled: January 20, 1988Date of Patent: July 11, 1989Assignee: Cetus CorporationInventors: Paula J. Shadle, Kirston E. Koths, Margaret Moreland, Nandini Katre
-
Patent number: 4797491Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--Xwherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from:--CO--Y--CONHNH.sub.2, a hydrazide; ##STR1## a hydrazine; ##STR2## a hydrazine; --CO--Y--NH--CONHNH.sub.2, a semicarbazide; and--CO--Z--NH--CSNHNH.sub.2, a thiosemicarbazide;wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue bridging the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected from--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --(a)wherein each n2 is independently 2-4 and ##STR3## wherein n3 is 2-6.Type: GrantFiled: March 17, 1986Date of Patent: January 10, 1989Assignee: Cetus CorporationInventors: Danute E. Nitecki, Margaret Moreland
-
Patent number: 4745180Abstract: A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is poorly or not at all water-soluble at pH 6-8 without such solubilizing agent, is selectively conjugated to at least one heparin fragment having a terminal 2,5-anhydro-D-mannose residue which has an aldehyde not involved in intramolecular hemiacetal formation.Type: GrantFiled: June 27, 1986Date of Patent: May 17, 1988Assignee: Cetus CorporationInventors: Margaret Moreland, Danute E. Nitecki